XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Segment Reconciliation

 

 

Year Ended December 31,

 

(in thousands)

 

2024

 

 

2023

 

Research and development:

 

 

 

 

 

 

Salaries and staff costs

 

$

6,903

 

 

$

5,930

 

Stock-based compensation

 

 

1,660

 

 

 

1,279

 

Clinical trials, outside services, and lab supplies

 

 

26,472

 

 

 

23,686

 

Facilities and other

 

 

1,817

 

 

 

1,962

 

Total research and development

 

$

36,852

 

 

$

32,857

 

Selling, general and administrative:

 

 

 

 

 

 

Salaries and staff costs

 

$

3,286

 

 

$

3,531

 

Stock-based compensation

 

 

3,100

 

 

 

3,230

 

Outside services and professional fees

 

 

4,369

 

 

 

4,133

 

Facilities and other

 

 

1,727

 

 

 

2,149

 

Total selling, general and administrative

 

$

12,482

 

 

$

13,043

 

Useful Life of Property and Equipment The estimated useful lives of the major classes of property and equipment are as follows:

 

 

Estimated Useful Lives

Furniture and office equipment

3 to 5 years

Leasehold improvements

4 to 6 years

Laboratory equipment

5 years

Property and equipment consisted of the following:

(in thousands)

 

As of December 31,
2024

 

 

As of December 31,
2023

 

Furniture and office equipment

 

$

1,053

 

 

$

1,067

 

Leasehold improvements

 

 

2,568

 

 

 

2,568

 

Laboratory equipment

 

 

1,414

 

 

 

1,355

 

Property and equipment, gross

 

 

5,035

 

 

 

4,990

 

Less—accumulated depreciation

 

 

(4,137

)

 

 

(3,752

)

Property and equipment, net

 

$

898

 

 

$

1,238

 

Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

Options to purchase Common Stock

 

 

8,334,765

 

 

 

6,650,954

 

Warrants to purchase Common Stock

 

 

2,807,353

 

 

 

2,807,948

 

Series A Convertible Preferred Stock

 

 

877

 

 

 

877

 

 

 

11,142,995

 

 

 

9,459,779